BioEnergy GmbH & Consultant

/Tag:BioEnergy GmbH & Consultant
­

The Cervipro Project progresses towards a new vaccine against cervical cancer

The coordinators of the Cervipro Project have recently met in Bionaturis facilities in Jerez with the goal of continue progressing in the development of the vaccine. In particular, Michael Götz (from the German Company BioEnergy GmbH & Consultant) and Martin Müller and Caroline Odenwald (from German Cancer Research-DKFZ) were the attendants. From Bionaturis, Elena de la Torre (Project Manager); Felix Risco (CTO) and Juan Jose Infante (CSO) were the participants.

The aim of the Cervipro Project is the development of a cost-effective vaccine against the Human Papilomavirus, which causes cervical cancer. This project receive funding from the Eurostars-2 Programme with co-funding from CDTI and the Research and Innovation Horizon 2020 Framework Programme from European Union (further information in the Relevant info published in 2015, only in Spanish)

The Cervipro Project –which started at the beginning of 2016- continues with several advances, such as the growing of the plants that will produce the vaccine and the experimental design of purification.

“Although we are in an early stage, the project is accomplishing the planned milestones. The participating companies and institutions are providing the necessary resource and Cervipro is moving towards its final goal. We are conscious that there is still a long way but we are convinced that we are in the right one”, Michael Götz, from BioEnergy GmbH & Consultant, has stated as leader of the Project.

With this project, Bionaturis Group is taking part in an alternative strategy to produce this drug in a cost-effective way, to make it affordable to the most needy regions, in other words, contributing to a global access to health. Specifically, Bionaturis Group is in charge of the development of the purification process of the vaccine as well as its analytical classification.

From Bionaturis, Elena […]

May 18th, 2017|Blog english|Comments Off on The Cervipro Project progresses towards a new vaccine against cervical cancer

The Cervipro Project progresses after a meeting in Heildelberg

The project devoted to the development of a cost-effective vaccine against cerivcal cancer, called Cervipro, continues progressing after the meeting held last week among Elena de la Torre, Project Manager at Bionaturis, and the representatives of the German Cancer Research Center (DKFZ) and the company BioEnergy GmbH & Consultant, as leaders of the consortium.

The meeting, held in the facilities of the research center in Heildelberg (Germany), was useful to monitor the contributions and actions of each member, as well as to set the next milestones in the development. Besides our Project Manager, Elena de la Torre, the attendees were Michael Götz (from BioEnergy GmbH & Consultant), Martin Müller and Caroline Odenwald (from DKFZ).

The goal of the Cervipro Project is to obtain a cost-effective vaccine against the Human Papilomavirus, which causes the cervical cancer. This project receives funding from the Eurostars-2 Programme with co-funding from CDTI and the Research and Innovation Horizon 2020 Framework Programme from European Union.

Taking part in an alternative strategy to produce the drug in a cost-effective way to make it affordable for the most highly impacted regions, Bionaturis Group is following its vision of ‘A Global Access To Health’.

About Bionaturis

Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).

February 4th, 2016|Blog english|Comments Off on The Cervipro Project progresses after a meeting in Heildelberg

Bionaturis Group takes part in the development of a vaccine against cervical cancer

The Centre for the Development of Industrial Technology (CDTI, in Spanish) has granted an incentive of 184.847,40 Euros to the company from the European Programme Eurostars
The project is led by the German company BioEnergy GmbH & Consultant with participation from the German Cancer Research Center

Jerez de la Frontera, January 12nd 2016. Bionaturis Group will take part in the development of a cost-effective and possibly oral vaccine against cervical cancer. The initiative, led by the German company BioEnergy GmbH & Consultant with the participation of the German Cancer Research Center, receives funding from the Eurostars-2 Programme with co-funding from CDTI and the Research and Innovation Horizon 2020 Framework Programme from European Union.

According to the World Health Organization (WHO), developing countries suffer the highest impact from cervical cancer, which is caused by the Human Papillomavirus (HPV). Currently available vaccines are at a price point that makes them unaffordable for most people in developing countries. In addition to the loss of human lives, this circumstance leaves a large gap in the global coverage against the disease. With this project, Bionaturis Group is taking part in an alternative strategy to produce a cost-effective vaccine that will be affordable for the most highly impacted regions, following its vision of ‘A Global Access To Health’.

“This project is a real and relevant challenge for Bionaturis because, with it, we are expanding our horizons. Our acquired technological expertise in both vaccine development and cost effective manufacturing platforms lets us face this initiative with the realistic goal of providing to the population at risk a first-in-class drug that will be affordable given the social and economic conditions of their countries”, Bionaturis CSO, Juan Jose Infante, has stated.

The WHO highlights that cervical cancer caused the […]

January 12th, 2016|Blog english, Press Releases|Comments Off on Bionaturis Group takes part in the development of a vaccine against cervical cancer

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR